Sublingual Epinephrine Tablet for Rapid Blood Pressure Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current epinephrine autoinjectors are bulky, costly, have a short shelf-life, and pose challenges due to needle fear and potential misuse, while epinephrine's oral administration is hindered by rapid degradation and poor bioavailability.
Innovation Solution
Development of sublingual l-epinephrine tablets that disintegrate under the tongue, with methods to prevent swallowing and ensure absorption, maintaining elevated plasma epinephrine levels for extended periods through consecutive dosing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If epinephrine autoinjectors are used, then rapid blood pressure restoration is achieved, but device bulkiness and cost increase
Solution Approach 1:
The patent replaces the mechanical injection system (autoinjector needle and syringe mechanism) with a chemical delivery system (sublingual tablet formulation). The epinephrine is delivered through mucosal absorption in the mouth rather than parenteral injection, eliminating the need for bulky mechanical injection devices while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent introduces the sublingual mucosa as an intermediary delivery route. Instead of direct intravenous or intramuscular injection, the epinephrine tablet acts as an intermediary that dissolves in the mouth and allows drug absorption through the mucosal membrane, providing a middle ground between oral and injectable routes.
2Reliability
If epinephrine autoinjectors are used, then emergency treatment capability is provided, but shelf-life is limited
Solution Approach 1:
The patent changes the physical state and formulation parameters of epinephrine from a liquid solution in an autoinjector to a solid tablet formulation. This parameter change from liquid to solid state, combined with specific excipients and coating, extends the shelf-life while maintaining the drug's therapeutic capability for emergency treatment.
3Ease of operation
If oral epinephrine administration is used, then device simplicity is improved, but bioavailability is poor due to rapid degradation
Solution Approach 1:
The patent uses the sublingual mucosa as an intermediary absorption route that bypasses the gastrointestinal tract and first-pass metabolism. The mucosal membrane serves as a direct portal to systemic circulation, maintaining high bioavailability while using simple oral administration.
Solution Approach 2:
The patent replaces the gastrointestinal absorption pathway with mucosal absorption in the mouth. This substitution avoids the degradative environment of the stomach and intestinal enzymes, preserving epinephrine bioavailability while maintaining the simplicity of oral tablet administration.
4Volume of moving object
If sublingual tablets are used, then portability and shelf-life are improved, but drug absorption must be ensured against swallowing
Solution Approach 1:
The patent incorporates disintegrating agents in the tablet formulation that activate upon contact with saliva, causing the tablet to break apart rapidly. This preliminary action of disintegration exposes the epinephrine for rapid mucosal absorption before swallowing can occur, ensuring reliable drug delivery.
Solution Approach 2:
The patent converts the potentially harmful effect of swallowing (which would degrade epinephrine) into a beneficial mechanism. Saliva, which could wash the drug away, instead triggers tablet disintegration and facilitates mucosal absorption. The act of swallowing is delayed or prevented long enough for sufficient absorption to occur.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Provides a safe, reliable, and pain-free method to sustain elevated plasma epinephrine levels, effectively mimicking injectable epinephrine formulations, ensuring blood perfusion and overcoming limitations of traditional autoinjectors.
Implementation Method 1
These methods are especially important when l-epinephrine injection is not available or not possible. The inventive methods can sustain life and restore proper blood perfusion when someone is having cardiopulmonary difficulty until medical help or transport can arrive.
Implementation Method 2
Development of sublingual l-epinephrine tablets that disintegrate under the tongue
Data Source
AI summary
The present invention provides novel methods of mimicking epinephrine plasma pharmacokinetic parameters/plasma epinephrine levels of an at least one l-epinephrine injection in humans with an at least one dosage of a sublingual l-epinephrine formulation; and includes methods of maintaining constant elevated plasma epinephrine level(s) by the consecutive dosing of sublingual l-epinephrine. These methods are especially important when l-epinephrine injection is not available or not possible. The present invention allows small, l-epinephrine sublingual tablets to be carried by soldiers and others, such as in a remote location or battlefield, when emergency medical services are not readily available or accessible. The inventive methods can sustain life and restore proper blood perfusion when someone is having cardiopulmonary difficulty until medical help or transport can arrive.